laboratory staff was statistically highly significant, but no difference was demonstrated between patients on anticoagulant treatment and those not receiving it. Our results show that the increase in the functional AT III concentration (measured by coagulation and chromogenic assays) observed in patients on oral anticoagulants is probably due to the effects of age and underlying disease rather than to the anticoagulant treatment itself.
Decreased plasma levels of AT III are associated with an increased incidence of thromboembolic disease, as seen in congenital deficiency, in women taking oral contraceptives with high oestrogen content, and during the postoperative period (for recent review see Barrowcliffe et 
Results
The results obtained with the PAT assay are shown in Figure 1 . The mean values were 103 4 % for laboratory controls, 117-9 % for patients not on oral anticoagulants, 130-2% for group 1 anticoagulated patients, 117-7% for group 2, and 1171 % for group 3. The PAT values were significantly higher in hypertensive patients and in groups 1 and 2 than in the laboratory controls. Group 3 was too small for analysis.
AT III levels measured by the chromogenic assay are shown in Figure 2 . Again laboratory controls showed lower values than the patients, and there was no difference between different patient groups. Mean Chrom AT III values were 94-2 % for laboratory controls, 110-5 % for hypertensive patients, 106-5 % for group 1 patients on anticoagulants, 105-6 % for group 2, and 111-5 % for group 3. Bull, Mackie, Brozovic, and Woodings We have also followed the AT III concentration, using the chromogenic assay, in three patients starting anticoagulant treatment (Fig. 4) . Case 1 received oral anticoagulants only and his AT III levels remained higher than normal throughout the period of observation. Cases 2 and 3 were given heparin and warfarin during the first three days of therapy, and warfarin alone thereafter. Their AT III levels on the first day of treatment were lower than in Case 1. The AT III concentration showed a slight rise when heparin was discontinued.
The results of the immunological assay are shown in Figure 3 . Laboratory controls had higher mean AT III antigen (1041 %) than hypertensive patients (93-9%), anticoagulated patients group 1 (98-6%), group 2 (96-2%), and group 3 (90-2%). These differences were significant (Table 2 ). There was no correlation between Thrombotest values and any of the AT III modalities measured. A fall in plasma AT III levels during heparin therapy is well documented, as is the subsequent rise while patients are given oral anticoagulants alone.314 Our observations on three patients confirm these findings and may explain the rise in AT III level seen during the early stages of anticoagulant therapy; this may well be the return to high pretreatment values after the heparin-induced fall. A larger series of patients tested regularly before, during, and after heparin and warfarin treatment is required to clarify this problem.
